Spoken Alpha
BIOMARIN PHARMACEUTICAL INC
BioMarin Pharmaceutical manufactures and commercializes medicines for rare genetic diseases, including eight approved therapies such as VOXZOGO for achondroplasia and enzyme replacement therapies for mucopolysaccharidosis disorders, along with a pipeline of clinical-stage candidates.
BIOMARIN PHARMACEUTICAL INC is a Healthcare company operating in Biotechnology with a $12.49B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 25, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BMRN.
$ curl https://api.spokenalpha.com/v1/companies/BMRNFAQ
Spoken Alpha indexes BMRN's earnings call transcripts at https://spokenalpha.com/companies/BMRN. Each call links to attributed speakers and parsed analyst Q&A. BIOMARIN PHARMACEUTICAL INC's own investor relations page is at https://investors.biomarin.com/overview/default.aspx.
BIOMARIN PHARMACEUTICAL INC (BMRN) held its most recent earnings call on 2026-05-04, covering fiscal Q1 2026.
BIOMARIN PHARMACEUTICAL INC (BMRN) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-25 | — | $1.14 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $0.90 | $0.79 | +13.9% | $989.7M | — | — | EODHD |
| Q1 FY2026 | 2026-05-03 | $0.76 | $0.91 | -16.5% | $766.2M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $0.46 | $0.81 | -43.5% | $874.6M | — | — | EODHD |
| Q3 FY2025 | 2025-10-26 | $0.12 | $0.34 | -64.7% | $776.1M | — | — | EODHD |
| Q2 FY2025 | 2025-08-03 | $1.44 | $1.03 | +39.8% | $825.4M | — | — | EODHD |
| Q1 FY2025 | 2025-04-30 | $1.13 | $0.95 | +18.9% | $745.1M | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $0.92 | $0.74 | +24.6% | $747.3M | — | — | EODHD |
| Q3 FY2024 | 2024-10-28 | $0.55 | $0.52 | +5.8% | $745.7M | — | — | EODHD |
| Q2 FY2024 | 2024-08-04 | $0.96 | $0.60 | +60.0% | $712.0M | — | — | EODHD |
| Q1 FY2024 | 2024-04-23 | $0.71 | $0.60 | +18.3% | $648.8M | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $0.18 | $0.23 | -21.7% | $646.2M | — | — | EODHD |
| Q3 FY2023 | 2023-10-31 | $0.46 | $0.48 | -4.2% | $581.3M | — | — | EODHD |
| Q2 FY2023 | 2023-07-30 | $0.54 | $0.47 | +14.9% | $595.3M | — | — | EODHD |
| Q1 FY2023 | 2023-04-25 | $0.60 | $0.40 | +50.0% | $596.4M | — | — | EODHD |
| Q4 FY2022 | 2023-02-26 | $-0.00 | $-0.07 | +98.1% | $537.5M | — | — | EODHD |
| Q3 FY2022 | 2022-10-25 | $0.45 | $0.43 | +4.7% | $505.3M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $0.58 | $0.53 | +9.4% | $533.8M | — | — | EODHD |
| Q1 FY2022 | 2022-04-26 | $0.54 | $0.46 | +17.4% | $519.4M | — | — | EODHD |
| Q4 FY2021 | 2022-02-22 | $-0.32 | $-0.32 | 0.0% | $449.8M | — | — | EODHD |
Source: EODHD. BMRN reported actuals as published; sparse fields render as —.